Global Information
회사소개 | 문의 | 위시리스트

세계의 줄기세포 의약품 제휴 계약 동향

Global Stem Cell Partnering 2014-2019: Deal trends, players and financials

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2019년 05월 상품 코드 355309
페이지 정보 영문 170+ Pages
가격
US $ 2,995 ₩ 3,654,000 PDF by E-mail (Single User License)
US $ 4,495 ₩ 5,484,000 PDF by E-mail (Multi user license - 2 to 5 Users)
US $ 8,995 ₩ 10,975,000 PDF by E-mail (Multi User Site License - 6+ Users)
US $ 14,995 ₩ 18,296,000 PDF by E-mail (Global license)


세계의 줄기세포 의약품 제휴 계약 동향 Global Stem Cell Partnering 2014-2019: Deal trends, players and financials
발행일 : 2019년 05월 페이지 정보 : 영문 170+ Pages

줄기세포 의약품에 관련된 각종 제휴 계약 동향에 대해 조사했으며, 최근 체결된 각종 계약 동향, 대규모 계약 및 대형 사업자에 의한 계약의 개요, 계약·개발 단계·치료 분야·기술 종류별로 정리하여 전해드립니다.

제1장 서론

제2장 줄기세포 의약품 관련 계약 동향

  • 서론
  • 과거 수년간 제휴 동향
  • 제휴 계약에서 가장 활발한 사업자
  • 제휴 계약 : 계약 종류별
  • 제휴 계약 : 치료 분야별
  • 제휴 계약의 조건
    • 거래 총액
    • 계약 선불금
    • 마일스톤 지불
    • 로열티율

제3장 주요 계약

  • 서론
  • 주요 계약 : 계약액별

제4장 제휴 계약에서 가장 활발한 사업자

  • 서론
  • 제휴 계약에서 가장 활발한 사업자
  • 제휴 계약에서 가장 활발한 사업자의 개요

제5장 제휴 계약 디렉토리

  • 서론
  • 제휴 계약 디렉토리

제6장 줄기세포 의약품 관련 계약 : 기술 종류별

제7장 제휴 계약 리소스 센터

  • 온라인 제휴
  • 제휴 이벤트
  • 제휴 계약 관련 자료

부록 1 : 제휴 계약 - 기업별(A-Z)

부록 2 : 제휴 계약 - 개발 단계별

  • Discovery
  • 전임상
  • 제I상
  • 제II상
  • 제III상
  • 신청 단계
  • 출시
  • 조제 단계

부록 3 : 제휴 계약 - 종류별

  • 자산 구입
  • 양도
  • 바이오의약품 아웃라이선싱
  • 공동 개발
  • 공동 R&D
  • 공동 판매
  • 공동 프로모션
  • CRADA
  • 크로스 라이선싱
  • 개발
  • 유통 판매
  • 주식 구입
  • 평가
  • 조성
  • 조인트 벤처
  • 라이선싱
  • 소송
  • 제조
  • 마케팅
  • 물질 이동
  • 옵션
  • 프로모션
  • 연구
  • 합의
  • 스핀아웃
  • 서브 라이선스
  • 공급
  • 기술 이전
  • 계약해제
  • 보증

부록 4 : 제휴 계약 - 치료 분야별

부록 5 -제휴 종류 정의

About Wildwood Ventures

도표

KSA 16.04.11

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

The Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in stem cell partnering

Deal terms analysis

Partnering agreement structure

Partnering contract documents

Top deals by value

Most active dealmakers

Average deal terms for stem cells

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 200 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Stem Cell dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Stem Cell deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Stem Cell dealmaking with a brief summary followed by a comprehensive listing of Stem Cell deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Stem Cell partnering deals signed and announced since Jan 2014. The chapter is organized by specific Stem Cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Key benefits

Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Stem Cell deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Stem Cell agreements with numerous real life case studies
  • Detailed access to actual Stem Cell contracts entered into by leading biopharma companies
  • Identify most active Stem Cell dealmakers since 2014
  • Insight into terms included in a Stem Cell partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Stem Cell trends and structure of deals entered into by leading companies worldwide.

Stem Cell Partnering Terms and Agreements includes:

  • Trends in Stem Cell dealmaking in the biopharma industry since 2014
  • Analysis of Stem Cell deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Stem Cell deals
  • Access to Stem Cell contract documents
  • Leading Stem Cell deals by value since 2014
  • Most active Stem Cell dealmakers since 2014

In Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 200 Stem Cell deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of stem cell deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of stem cell agreements with numerous real life case studies
  • Detailed access to actual stem cell contracts entered into by leading biopharma companies
  • Identify most active stem cell dealmakers since 2014
  • Insight into terms included in a stem cell partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Stem Cell dealmaking

  • 2.1. Introduction
  • 2.2. Stem Cell partnering over the years
  • 2.3. Most active Stem Cell dealmakers
  • 2.4. Stem Cell partnering by deal type
  • 2.5. Stem Cell partnering by therapy area
  • 2.6. Deal terms for Stem Cell partnering
    • 2.6.1 Stem Cell partnering headline values
    • 2.6.2 Stem Cell deal upfront payments7
    • 2.6.3 Stem Cell deal milestone payments
    • 2.6.4 Stem Cell royalty rates

Chapter 3 - Leading Stem Cell deals

  • 3.1. Introduction
  • 3.2. Top Stem Cell deals by value

Chapter 4 - Most active Stem Cell dealmakers

  • 4.1. Introduction
  • 4.2. Most active Stem Cell dealmakers
  • 4.3. Most active Stem Cell partnering company profiles

Chapter 5 - Stem Cell contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Stem Cell contracts dealmaking directory

Chapter 6 - Stem Cell dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Stem Cell deals by company A-Z
  • Appendix 2 - Stem Cell deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - Stem Cell deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty
  • Appendix 4 - Stem Cell deals by therapy area
  • Appendix 5 -Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Stem Cell partnering since 2014
  • Figure 2: Active Stem Cell dealmaking activity since 2014
  • Figure 3: Stem Cell partnering by deal type since 2014
  • Figure 4: Stem Cell partnering by disease type since 2014
  • Figure 5: Stem Cell deals with a headline value
  • Figure 6: Stem Cell deals with an upfront value
  • Figure 7: Stem Cell deals with a milestone value
  • Figure 8: Stem Cell deals with a royalty rate value
  • Figure 9: Top Stem Cell deals by value since 2014
  • Figure 10: Most active Stem Cell dealmakers since 2014
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top
전화 문의
F A Q